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survival benefit of kidney transplantation.
Background. Longer waiting times may limit the survival
benefit of kidney transplantation in older patients or those with
a high burden of comorbid disease.
Methods. We performed a longitudinal study of mortality
among 63,783 transplant candidates who started dialysis be-
tween April 1995 and December 2000. We determined the rel-
ative risk (RR) of death and increase in life expectancy among
subjects who received a first deceased donor transplant after dif-
ferent waiting times compared to subjects who had equivalent
waiting times but remained on dialysis.
Results. Transplant recipients had a lower long-term RR of
death and the risk reduction was greatest in recipients with
longer waiting times (RR of death 12 months after transplan-
tation for recipients with waiting times of 0, 1, 2, 3 years was
0.49, 0.43, 0.38, 0.34, P = 0.0006).The average increase in life
expectancy in transplant recipients was 9.8 years and was lower
in older recipients and recipients with comorbid conditions. In-
creased waiting times from 1 to 3 years only moderately de-
creased the overall survival benefit of transplantation from 7.1
to 5.6 years, and all subjects derived a survival benefit from
transplantation with waiting times up to 3 years.
Conclusion. These findings do not support limiting access to
transplantation for otherwise suitable candidates on the basis
of longer anticipated waiting times.
Transplantation is the preferred treatment for patients
with end-stage kidney disease. Compared to patients
treated with dialysis, transplant recipients live longer,
have improved quality of life, and consume fewer health
care resources [1–3]. The survival benefit of transplan-
tation compared to dialysis was demonstrated in a co-
Key words: kidney transplantation, patient survival, waiting time, co-
morbid conditions.
Received for publication March 30, 2005
and in revised form April 27, 2005, and June 2, 2005
Accepted for publication June 13, 2005
C© 2005 by the International Society of Nephrology
hort of patients activated to the transplant waiting list
in the United States between 1991 and 1996 [1]. Since
that time, both waiting times for transplantation and the
burden of comorbid disease in patients seeking transplan-
tation have increased. In the current era, the shortage of
available organs is the dominant issue. As of March 2005
there were 61,192 patients on the United Network of Or-
gan Sharing waiting list for kidney transplantation [4].
By 2010, a projected 95,000 patients will be on the kidney
waiting list in the United States, and waiting times of a
decade or more are anticipated [5, 6]. The success of kid-
ney transplantation has also contributed to the increased
demand, and patients previously denied transplantation
because of age or comorbid conditions now routinely
seek and receive transplants. For example, between 1991
and 2001, the proportion of deceased donor kidney trans-
plant recipients in the United States who were older than
50 years increased from 29.5% to 47.7% [7].
Previous work evaluating the survival benefit of trans-
plantation compared to dialysis did not consider the
impact of death or progression of comorbidity while
awaiting transplantation and, hence, its applicability to
the care of patients under current conditions is uncertain
[1]. As the discrepancy between the supply and demand
for kidney transplantation grows, pressure to preferen-
tially allocate organs to patients with the greatest chance
of benefit is likely to increase. The purpose of this study
was to determine the impact of increased waiting time
and comorbid disease on the survival benefit of trans-
plantation in the current era.
METHODS
Data from the United States Renal Data System were
used for this study. There were 361,254 subjects under
the age of 75 years who began their first chronic dialysis
treatment between April 1, 1995 and December 31, 2000.
We studied the subset of 63,783 subjects who were also
active on the kidney transplant waiting list. Descriptive
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statistics included the chi-square test or ANOVA as
appropriate.
Survival was determined from the time of first activa-
tion to the transplant waiting list. Patients were followed
until death, living donor, or multiorgan transplant, or the
end of follow-up (December 31, 2000). Follow-up con-
tinued for subjects who were removed from the waiting
list or had transplant failure. The relative risk of death in
transplant recipients compared to subjects who remained
on the waiting list with the same amount of waiting time
was determined in a Cox regression analysis. Because
mortality among transplant recipients increased sharply
during the perioperative period and then declined be-
low the rate observed in comparable subjects remaining
on dialysis, the coefficient of the transplant status vari-
able was allowed to vary with time after transplantation.
We also permitted the risk of death after transplantation
to differ in subjects with longer waiting times prior to
transplantation with the use of time-varying coefficients.
Analyses were adjusted for age, gender, race, cause of
end-stage renal disease, comorbid conditions defined at
the time of dialysis initiation (ischemic heart disease, con-
gestive heart failure, stroke, peripheral vascular disease),
duration of dialysis exposure prior to wait-listing, and
year of placement on the transplant waiting list.
The projected number of life years remaining was de-
termined in time-dependent parametric survival analyses
that included the same covariates in the Cox regression
analysis described above. The projections of life years
remaining in wait-listed dialysis subjects were based on
follow-up from activation to the waiting list until live
donor or multiorgan transplantation, death, or end of
study, and therefore included the impact of death on
dialysis during the wait-list period. These projections as-
sumed a Weibull distribution for the survival times in
subjects remaining on dialysis, and a log-normal distri-
bution for the survival times in subjects who received a
transplant, based on goodness of fit tests and graphical
comparison of the parametric hazard curves with the em-
piric hazards. [8] All analyses were performed with SAS,
version 8.2 (SAS Institute, Cary, NC, USA). The study
was approved by our university hospital ethics review
board.
RESULTS
Of the 63,783 wait-listed dialysis subjects studied,
19,666 received a first deceased donor kidney transplant
after a median waiting time of 0.65 years (5th–95th per-
centile, 24 days–2.65 years). An additional 8568 received
either live donor or multiorgan transplants, while 35,549
subjects did not receive transplants and remained on dial-
ysis. Compared to subjects who remained on dialysis, re-
cipients of first deceased donor kidney transplants were
younger and more likely to be male and of white race
(P < 0.001 for all group comparisons) (Table 1). Trans-
plant recipients were also less likely to have diabetic
kidney disease, ischemic heart disease, or congestive
heart failure (P < 0.001 for all group comparisons)
(Table 1). Among transplant recipients with waiting time
≤12 months, the proportion of recipients aged ≥60 years
(20%), of white race (72%), with diabetic kidney disease
(34%), history of ischemic heart disease (8%), peripheral
vascular disease (5%), congestive heart failure (12%), or
cerebrovascular accident (3%) was higher than among re-
ceipts with waiting times ≥36 months (11%, 51%, 23%,
6%, 3%, 9%, 2%; P < 0.001 for all group comparisons).
The relative risk of death in transplant recipients who
received transplants after 0, 1, 2, or 3 years of waiting
time compared to wait-listed subjects with equal wait-
ing time who remained on dialysis is shown in Figure 1.
All transplant recipients had an increased relative risk of
death in the immediate posttransplant period. The rela-
tive risk of death then rapidly declined, and transplant
recipients had a lower long-term relative risk of death.
The unadjusted annual death rates and hazard for mor-
tality in dialysis subjects increased with each additional
year on the waiting list (Table 2, Fig. 2A). In contrast, the
annual death rates and hazard for morality in transplant
recipients were similar in subjects who received trans-
plants after short or long waiting times (Table 2, Fig. 2B).
Consequently, the relative risk of death among transplant
recipients tended to decrease with increasing waiting
times, compared with subjects who remained on dialysis
(Fig. 1).
The projected years of life remaining for subjects who
received transplants after different waiting times and sub-
jects who remained on dialysis are shown in Table 3, as
well as the projected benefit in life years for transplant re-
cipients. The average projected benefit for subjects who
received a transplant at any time during follow-up was
9.8 years. The benefit of transplantation was inversely re-
lated to subject age and was lower in subjects with comor-
bid conditions. For example, transplant recipients who
were 0 to 19 years of age or ≥70 years at the time of ac-
tivation to the waiting list derived a projected survival
benefit of 17.2 and 3.7 additional life years, respectively,
compared with subjects of similar age who remained on
dialysis (Table 3).
The benefit of transplantation was greatest in sub-
jects who received transplants with the shortest waiting
time. However, the overall survival benefit associated
with transplantation was only moderately reduced, from
7.1 years after a waiting time of 1 year to 5.6 years after
a waiting time of 3 years (Table 3), and the survival ben-
efit of transplantation was observed in all subject groups
even after the maximum observed waiting time of 3 years.
The magnitude of the benefit associated with shorter
waiting time appeared most pronounced in younger sub-
jects [i.e., transplant recipients aged 0–19 had a 2.6 year
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Table 1. Characteristics of study subjects and comparison of transplant recipients and subjects who remained on dialysis during follow-up
Subjects who remained Subjects who Recipients of a
All subjects on on dialysis during received a live or first deceased
the waiting list follow-up multiorgan transplant donor transplant
(N = 63,783) (N = 35,549) (N = 8568) (N = 19,666)
Agea mean ± SD 47 ± 14 49 ± 13 42 ± 13 46 ± 14
Male% 60 58 60 62
Race%
White 61 55 75 68
Black 29 35 17 24
Asian 5 6 4 4
Native American 2 2 1 1
Other/unknown 3 3 2 2
Cause of ESRDb%
Diabetes 37 40 38 31
Glomerulonephritis 25 22 30 28
Other 38 38 33 41
Comorbid conditionsa%
Ischemic heart disease 9 10 7 8
Peripheral vascular disease 5 6 4 5
Congestive heart failure 13 15 9 11
Cerebrovascular accident 3 3 2 3
Listed before or at start of dialysis% 14 11 20 15
Months from first dialysis to wait-listingcmean ± SD) 12 ± 10 14 ± 11 8 ± 8 12 ± 9
a Defined at time of activation to transplant waiting list.
b End-stage renal disease.
c Patients wait-listed after dialysis initiation only.
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Fig. 1. The relative risk of death at different times after transplantation
in transplant recipients with progressively longer waiting times com-
pared to subjects who waited the same duration of time but remained
on dialysis is shown. Values were adjusted for recipient age, gender,
race, cause of end-stage kidney disease, comorbid conditions defined at
the time of dialysis initiation (ischemic heart disease, congestive heart
failure, stroke, peripheral vascular disease), duration of dialysis expo-
sure prior to transplantation, and year of placement on the transplant
waiting list.
decrease in the anticipated survival benefit with an in-
crease in expected waiting time from at least 12 to 36
months compared to a decrease of 0.6 years in recipients
aged ≥70 years (Table 3)].
DISCUSSION
In this longitudinal study of transplant candidates in the
United States, we found that transplant recipients had a
lower relative risk of death compared to wait-listed dial-
ysis patients with similar waiting times. Increased waiting
times were not characterized by a diminished benefit of
transplantation, but instead were associated with a lower
relative risk of death compared with remaining on dial-
ysis. The increased risk reduction among transplant re-
cipients with longer waiting times was the result of high
mortality among subjects who remained on dialysis for
long time periods and the consistent reduction in mor-
tality after transplantation that was not attenuated by
increased waiting times. Although the overall survival
benefit of transplantation was decreased with increased
waiting times, this decrement was small and subjects in all
age groups and with a variety of comorbid conditions de-
rived a survival advantage with transplantation up to the
maximum observed waiting time of 3 years. Our findings
do not support limiting access to transplantation based
on a perceived decrease in survival benefit with increased
waiting time and identify the need to improve the survival
of patients who remain on dialysis awaiting transplanta-
tion for prolonged periods.
As originally reported by Wolfe et al, we found that the
relative risk of death in transplant recipients compared to
wait-listed dialysis subjects was higher in the immediate
postoperative period but decreased rapidly thereafter, re-
sulting in a long-term survival advantage associated with
transplantation [1]. Notably, we found that the relative
risk of death at any time point after transplantation con-
tinued to decrease with longer waiting times, relative to
those who remained on dialysis. There were 2 factors
that contributed to this unanticipated finding. First, there
was a predictable increase in the absolute risk of death
with time among subjects who remained on dialysis. This
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Table 2. Unadjusted annual death ratesa among wait-listed patients during different waiting periods and among transplant recipientsb with
different waiting times prior to transplantation
Time after activation to waiting list Waiting time prior to transplantation
0–12.0 12.1–24.0 24.1–36.0 ≥36.0 0–12 12–24 24–36 ≥36
months months months months months months months months
All patients 4.5 8.0 9.3 11.2 4.1 4.1 4.0 5.4
4.3–4.6 7.6–8.3 8.8–9.9 10.3–12.0 3.8–4.4 3.7–4.5 3.3–4.7 4.2–6.8
Age
0–19 1.8 2.2 1.6 2.2 1.1 2.6 0.9 0
1.2–2.8 1.2–4.0 0.5–5.0 0.7–6.8 0.7–1.8 1.6–4.6 0.1–6.6
20–39 2.9 4.8 5.3 5.6 1.9 1.5 2.1 1.2
2.6–3.2 4.2–5.3 4.5–6.2 4.6–6.9 1.6–2.3 1.1–2.0 1.3–3.3 0.5–2.9
40–59 4.6 8.0 9.2 12.1 4.4 4.6 3.3 6.8
4.3–4.9 7.5–8.5 8.5–10.0 10.9–13.3 4.0–4.8 4.0–5.3 2.6–4.3 5.1 -9.1
60–64 6.3 10.6 15.2 18.3 7.0 7.5 9.5 11.7
5.7–7.1 9.3–12.0 13.1–17.7 15.1–22.3 6.0–8.3 5.8–9.8 6.4–14.1 6.5–21.2
65–69 6.3 15.0 16.1 18.6 8.5 7.4 15.1 9.8
5.5–7.2 13.2–17.0 13.3–19.4 14.5–23.9 7.1–10.2 5.2–10.4 9.8–23.2 4.1 -23.6
>70 8.7 18.6 23.1 25.2 9.9 8.7 12.1 26.1
7.1–10.7 15.1–22.9 17.3–31.0 16.6–38.3 7.4–13.2 4.8–15.7 3.9–37.5 3.7–185
Gender
Female 4.6 7.5 8.8 11.1 4.2 4.0 2.6 6.1
4.3–4.9 7.0–8.1 7.9–9.7 9.9–12.4 3.8–4.7 3.4–4.8 1.8–3.6 4.2–8.8
Male 4.3 8.3 9.8 11.2 4.0 4.1 4.9 4.9
4.1–4.6 7.8–8.8 9.0–10.6 10.1–12.4 3.7 -4.4 3.6–4.6 4.0–6.0 3.6–6.8
Race
white 5.0 9.6 11.5 15.3 4.3 3.9 4.3 6.0
4.7–5.2 9.1–10.1 10.7–12.4 13.9–16.8 4.0–4.6 3.5–4.5 3.5–5.3 4.4–8.1
black 3.8 6.3 7.1 7.1 3.8 4.6 3.6 5.4
3.5–4.2 5.7–6.8 6.3 -,8.0 6.1–8.2 3.3–4.4 3.7–5.5 2.6–5.2 3.6–8.2
Asian 3.0 4.5 6.2 5.9 3.3 2.8 1.1 2.4
2.4–3.7 3.6–5.7 4.7–8.3 4.0–8.6 2.3 4.7 1.6–4.9 0.3–4.2 0.6 -,9.4
Native American 4.2 6.7 9.2 12.0 5.2 3.7 7.1 0
2.9–5.9 4.7–9.7 6.1–14.0 7.6–18.8 3.0–9.2 1.4–9.9 2.3–22.0
Cause of ESRD
Diabetes 7.0 13.7 15.8 20.2 6.0 7.0 6.5 10.3
6.6–7.4 12.9–14.6 14.6–17.2 18.2–22.4 5.5–6.6 6.0–8.1 4.9–8.6 7.1–15.0
Glomerulonephritis 2.4 4.2 5.6 6.2 2.8 2.4 3.1 3.2
2.2–2.7 3.7–4.8 4.8–6.5 5.2–7.6 2.4–3.2 1.9–3.1 2.2–4.4 1.8–5.6
Other 3.4 5.3 6.5 7.9 3.6 3.4 3.2 4.6
3.1–3.6 4.9–5.8 5.8–7.3 6.9–9.1 3.2–4.0 2.9–4.0 2.4–4.3 3.2–6.6
Comorbid conditions
None 3.6 6.4 7.4 3.4 3.5 3.3 4.9
3.4–3.8 6.0–6.8 6.8–8.0 3.2–3.7 3.1–3.9 2.7–4.1 3.7–6.4
Ischemic heart disease 7.6 15.6 18.1 19.9 7.7 8.1 7.2 4.3
6.8–8.5 14.0–17.4 15.6–21.0 16.3–24.2 6.5–9.1 6.0–10.9 4.3–12.2 1.4–13.4
Peripheral vascular disease 8.7 18.5 17.4 21.4 6.5 8.9 11.3 14.4
7.6–9.9 16.2–21.1 14.2–21.3 16.6–27.6 5.1 -8.2 6.2–12.7 6.3–20.4 6.0–34.5
Congestive heart failure 7.7 13.5 16.6 17.3 8.1 7.6 9.4 6.1
7.0–8.4 12.3–14.9 14.6–18.9 14.6–20.6 7.0–9.3 5.9–9.8 6.3–14.0 2.7–13.5
Cerebrovascular accident 8.4 13.0 17.3 18.0 6.7 9.2 6.0 11.4
7.0–10.0 10.6–16.0 13.3–22.5 12.4–26.0 4.9–9.1 5.9–14.3 2.2–15.9 3.7–35.5
aPer 100 patient years, point estimate, and 95% CI.
b Death rate at any time after transplantation in patients who received deceased donor kidney transplants after different waiting times.
increase (Fig. 2) was nearly linear but did plateau over
time, suggesting a survivor effect among wait-listed sub-
jects with longer waiting times. This increase in the risk
of death on dialysis may result from progressive cardio-
vascular disease in this population [9–11]. Our analysis
was designed to help clinicians decide whether to acti-
vate a particular patient on the waiting list. Therefore, to
avoid bias, subjects were included in analyses even if they
were removed from the waiting list. Therefore, some of
the increase in the absolute risk of death in dialysis sub-
jects over time may have been contributed by those who
were no longer active transplant candidates. Similarly, re-
liable information regarding wait-listed patients placed
“on hold” was not available and was not incorporated in
our analysis. Our findings suggest that as waiting times
for transplantation continue to increase, monitoring and
maintaining the medical fitness of transplant candidates
will become increasingly difficult.
The second factor contributing to the lower relative risk
of death in transplant recipients with longer waiting times
was the fact that the absolute risk of peri-transplantation
death appeared to be independent of waiting time. We
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Fig. 2. (A) The hazard and 95% CI for mortality among subjects who
remained on dialysis as a function of time since activation to the waiting
list. (B) The hazard for mortality at different time points after trans-
plantation for recipients who received first deceased donor kidney trans-
plants after different waiting times. Although the hazard for mortality
was higher during the immediate postoperative period among patients
with longer waiting times, overall the hazards were very similar among
transplant recipients with different waiting times.
hypothesized that the posttransplant risk of death would
be higher in subjects who received transplants after
longer waiting times due to progression of comorbid dis-
ease on dialysis, and therefore allowed the risk to vary
with waiting time. The finding that increased waiting
times did not increase the absolute risk of death after
transplantation suggests that there may be systematic dif-
ferences between the subjects who received transplants
after prolonged waiting times and those who remained
on dialysis that are unaccounted for in our multivariate
analysis. A selection bias is supported by the finding that
the proportion of transplant recipients ≥60 years and re-
cipients with diabetes or comorbid conditions decreased
as waiting times increased (Table 2).
Our projections of the survival benefit of transplanta-
tion account for both the waiting time for transplantation
and death prior to transplantation. Our projections differ
from the projections of life expectancy with transplanta-
tion provided by Wolfe et al, which were based on a sub-
group of patients who had survived the wait-list period to
receive a transplant [1]. Because our projections capture
the impact of death on the waiting list, they can be used
by clinicians to establish candidacy for transplantation at
the time patients seek activation to the waiting list. This
information is needed because of the significant cost and
workload related to activating and maintaining patients
on the waiting list [6, 12]. The magnitude of the antic-
ipated survival benefit can be used to provide patients
seeking transplantation with a reasonable expectation of
outcome, and may influence patient preference for trans-
plantation. Additionally, some patients may reasonably
be excluded from consideration if the anticipated waiting
time exceeds the projected life expectancy on dialysis.
We found that the increase in life years with trans-
plantation was greatest in transplant recipients with the
shortest waiting time. Importantly, the increased survival
benefit among transplant recipients with the shortest
waiting times was largely due to the progressive increase
in mortality among patients who remained on the wait-
ing list, rather than increased mortality among those who
received transplants after longer waiting times. Indeed,
we did not find a consistent increase in crude death rate
among transplant recipients with longer waiting times
(Table 2). These findings seem to differ from studies
which have shown an increased relative risk of graft loss
and or death [13, 14] among transplant recipients with
longer waiting times. It is difficult to compare the crude
death rates in our study to the risk ratios from a multi-
variate analysis used in these other studies. However, the
apparent differences between our findings and those in
other studies [13, 14] could be explained by the selection
of healthier patients for transplantation after longer wait-
ing times evident in our analysis. Since a relatively large
proportion of subjects received a transplant after a wait-
ing time of less than 1 year, the largest projected benefit
was seen in subjects who received a transplant at any time
during follow-up (after wait time of 0–3 years). The im-
pact of increased waiting time was variable with a larger
decrement in survival benefit among younger transplant
recipients and recipients with nondiabetic kidney disease.
Nonetheless, an apparent survival benefit of transplanta-
tion was observed in all subgroups and in subjects with
waiting times of as long as 3 years (Table 3).
When interpreting our findings, readers should con-
sider the inherent limitations of observational studies.
Our assessment of comorbid conditions was performed
when patients began their first treatment for end-stage
kidney disease and not at the time of transplantation,
and thus our analysis does not account for progression of
comorbid conditions that may have occurred during the
wait list period. It is plausible that progression of comor-
bid conditions may be different among patients who did
and did not receive transplants, such differences may im-
pact the survival benefit associated with transplantation
and would not be captured in our analysis. Nonetheless,
we believe the inclusion of comorbid conditions in our
analysis increases the understanding of the anticipated
survival benefit of transplantation compared to earlier
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Table 3. Expected life yearsa withb and withoutc transplantation and benefitd of transplantation
Transplant at Transplant after Transplant after Transplant after
any time during minimum waiting minimum waiting minimum waitingWithout follow-upe time of 1 year time of 2 years time of 3 yearstransplant
Expected Expected Expected Expected Expected
life years life years Benefit life years Benefit life years Benefit life years Benefit
All patients 7.9 17.7 9.8 15.0 7.1 13.9 6 13.5 5.6
(7.5,8.2) (16.7,18.7) (14.2,15.8) (13.1,14.6) (12.7,14.2)
Age
0–19 12.0 29.2 17.2 20.7 8.7 19.0 7 18.1 6.1
(9.2,14.7) (23.8,34.6) (16.6,24.9) (15.0,23.0) (14.3,21.9)
20–39 9.5 24.3 14.8 19.5 10 17.5 8 16.9 7.4
(8.8,10.1) (22.4,26.1) (18.0,21.0) (16.2,18.9) (15.6,18.2)
40–59 7.6 17.0 9.4 14.7 7.1 13.6 6 13.2 5.6
(7.3,8.0) (16.0,18.0) (13.8,15.5) (12.8,14.4) (12.4,14.0)
60–64 6.5 12.7 6.2 11.4 4.9 10.8 4.3 10.6 4.1
(6.1,6.9) (11.7,13.7) (10.5,12.3) (9.9,11.6) (9.8,11.4)
65–69 5.8 11.1 5.3 10.1 4.3 9.6 3.8 9.5 3.7
(5.4,6.2) (10.1,12.1) (9.2,11.0) (8.8,10.5) (8.7,10.4)
≥70 4.5 8.2 3.7 7.5 3 7.1 2.6 7.0 2.5
(4.0,4.9) (7.1,9.2) (6.5,8.5) (6.2,8.0) (6.1,7.9)
Male 7.9 18.2 10.3 15.4 7.5 14.2 6.3 13.8 5.9
(7.5,8.3) (17.2,19.3) (14.5,16.3) (13.3,15.0) (13.0,14.6)
Female 7.8 16.9 9.1 14.5 6.7 13.4 5.6 13.0 5.2
(7.4,8.1) (15.9,18.0) (13.6,15.4) (12.6,14.3) (12.2,13.8)
Race
White 7.1 16.3 9.2 13.6 6.5 12.5 5.4 12.1 5
(6.7,7.4) (15.4,17.2) (12.8,14.4) (11.8,13.2) (11.4,12.8)
Black 9.1 19.5 10.4 17.0 7.9 16.0 6.9 15.5 6.5
(8.6,9.6) (18.2,20.8) (15.9,18.1) (14.9,17.0) (14.5,16.6)
Asian 10.4 24.1 13.7 20.8 10.4 19.2 8.8 18.4 8
(9.3,11.5) (21.1,27.1) (18.2,23.3) (16.8,21.5) (16.2,20.7)
Native American 9.7 21.4 11.7 19.0 9.3 17.6 7.9 17.2 7.5
(8.3,11.2) (17.4,25.4) (15.4,22.5) (14.4,20.8) (14.0,20.4)
Cause Of ESRDf
Diabetes 5.4 11.4 6 9.6 4.2 9.1 3.7 8.8 2.4
(5.2,5.7) (10.7,12.0) (9.1,10.2) (8.6,9.6) (8.3,9.3)
Glomerulo-nephrititis 10.3 24.4 14.1 20.8 10.5 19.0 8.7 18.4 8.1
(9.6,11.0) (22.6,26.3) (19.2,22.4) (17.5,20.5) (17.0,19.8)
Other 9.3 21.6 12.3 18.3 9 16.8 7.5 16.2 6.9
(8.7,9.8) (20.2,23.1) (17.1,19.5) (15.6,17.9) (15.1,17.3)
Ischemic heart disease 7.0 14.9 7.9 12.8 5.8 12.0 5 11.6 4.6
(6.5,7.4) (13.7,16.2) (11.7,13.9) (11.0,13.0) (10.6,12.6)
Peripheral vascular disease 6.7 14.6 7.9 12.2 5.5 11.4 4.7 11.1 4.4
(6.2,7.2) (13.2,16.1) (11.0,13.4) (10.3,12.5) (10.0,12.2)
Congestive heart failure 6.8 13.5 6.7 11.8 5 11.0 4.2 10.7 3.9
(6.4,7.2) (12.5,14.5) (10.9,12.7) (10.1,11.8) (9.9,11.5)
Cerebrovascular accident 6.4 13.4 7 11.4 5 10.6 4.2 10.4 4
(5.8,7.0) (11.8,15.1) (10.0,12.8) (9.3,11.9) (9.1,11.6)
a Projected from the time of activation to the transplant waiting list. Projections based on a time-dependent parametric multivariate survival model. Point estimate
and 95% CI in years are shown.
b Assuming a log-normal distribution for graft failure times.
c Assuming a Weibull distribution for graft failure times.
d The difference in expected life years with and without transplantation.
e Includes N = 10,985 (56% of all transplant recipients during follow-up) who received transplants with waiting times of ≤1 year.
f End-stage renal disease.
studies regarding this subject, which did not include ad-
justment for comorbid conditions [1].
The limitations of projections based on incomplete
follow-up data have been highlighted recently in the
transplant literature [15]. Nonetheless, it is clear that pro-
jections remain a necessary and valuable component of
transplant-related research [16]. In making our projec-
tions we used goodness of fit tests and graphical com-
parisons in order to achieve the best approximation
between the parametric hazards and the empiric hazards.
Nonetheless, our projections are ultimately based on as-
sumptions regarding the distribution of survival times in
patients with relatively short follow-up and should be in-
terpreted with this understanding.
CONCLUSION
We demonstrate that the survival benefit of transplan-
tation is maintained with waiting times of up to 3 years in
all transplant candidates irrespective of age and comorbid
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disease status. These findings do not support limiting ac-
cess to transplantation for otherwise suitable candidates
on the basis of longer anticipated waiting times.
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